A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H.
Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11.
PMID:36369793
Blood transcriptome analysis revealed the crosstalk between severe COVID-19 and systemic lupus erythematosus.
Meng R, Zhang N, Yang F, Xu Z, Wu Z, Du Y.
J Infect. 2023 Apr;86(4):e104-e106. doi: 10.1016/j.jinf.2023.02.011. Epub 2023 Feb 10.
PMID:36775249
Severe pneumonia in Chinese patients with systemic lupus erythematosus.
Peng L, Wang Y, Zhao L, Chen T, Huang A.
Lupus. 2020 Jun;29(7):735-742. doi: 10.1177/0961203320922609. Epub 2020 May 13.
PMID:32403979
Organizing pneumonia as a possible pulmonary manifestation of systemic lupus erythematosus: Three cases and a review of literature.
Ito Y, Tamada T, Okunishi Y, Mizutani S, Yamamoto Y, Nakajima A.
Lupus. 2022 May;31(6):737-743. doi: 10.1177/09612033221088177. Epub 2022 Mar 26.
PMID:35341381
Systemic lupus erythematosus presenting as non-resolving pneumonia: a case report.
Stappers S, van der Graaff D, Hoffman I, Moorkens W, Hantson I, Stappaerts I, Nowé V, Vervliet L.